All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 11: Eye
Toggle Parent Pages
Print this page
Treatment of dry eye
Nutritional supplements for age-related macular degeneration
11.1 Administration of drugs to the eye
11.3 Anti-infective eye preparations
11.4 Corticosteroids and other anti-inflammatory preparations
11.5 Mydriatics and cycloplegics
11.6 Treatment of glaucoma
11.7 Local anaesthetics
11.8 Miscellaneous ophthalmic preparations
11.9 Contact lenses
Contact us about this page
11.8.3 Other miscellaneous preparations
First Line
Second Line
Specialist
Hospital Only
Holoclar
(Autologous human corneal epithelial cells)
- 79,000 - 316,000 cells/cm2 living tissue equivalent
Notes
- NICE TA467: Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) is recommended as an option in people with moderate to severe limbal stem cell deficiency after eye burns, only if the criteria specified in NICE TA467 are met (August 2017)
Voretigene neparvovec
- Concentrate and solvent for solution for injection 5 x 1012 vg/ml
Notes
- NICE HST11: Voretigene neparvovec (Luxturna) is recommended as an option for treating RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells (October 2019)
